Charts
|
APT |
Re:
APT Chart
|
|
EML333
|
4.6K |
1.8M |
0 |
10/11/20 |
10/11/20 |
Charts
|
4.6K
|
1.8M
|
0
|
|
ASX - By Stock
|
WBT |
Re:
Weebit - 2021and beyond
|
|
EML333
|
10K |
3.6M |
10 |
08/11/20 |
08/11/20 |
ASX - By Stock
|
10K
|
3.6M
|
10
|
|
ASX - By Stock
|
WBT |
Re:
Weebit - 2021and beyond
|
|
EML333
|
10K |
3.6M |
4 |
07/11/20 |
07/11/20 |
ASX - By Stock
|
10K
|
3.6M
|
4
|
|
ASX - By Stock
|
WBT |
Re:
Charts
|
|
EML333
|
4.9K |
2.0M |
1 |
06/11/20 |
06/11/20 |
ASX - By Stock
|
4.9K
|
2.0M
|
1
|
|
ASX - By Stock
|
WBT |
Re:
Charts
|
|
EML333
|
4.9K |
2.0M |
6 |
04/11/20 |
04/11/20 |
ASX - By Stock
|
4.9K
|
2.0M
|
6
|
|
ASX - By Stock
|
WBT |
Re:
Charts
|
|
EML333
|
4.9K |
2.0M |
0 |
04/11/20 |
04/11/20 |
ASX - By Stock
|
4.9K
|
2.0M
|
0
|
|
ASX - By Stock
|
WBT |
Re:
Charts
|
|
EML333
|
4.9K |
2.0M |
5 |
03/11/20 |
03/11/20 |
ASX - By Stock
|
4.9K
|
2.0M
|
5
|
|
ASX - By Stock
|
WBT |
Re:
Charts
|
|
EML333
|
4.9K |
2.0M |
15 |
02/11/20 |
02/11/20 |
ASX - By Stock
|
4.9K
|
2.0M
|
15
|
|
ASX - By Stock
|
WBT |
Re:
Charts
|
|
EML333
|
4.9K |
2.0M |
3 |
02/11/20 |
02/11/20 |
ASX - By Stock
|
4.9K
|
2.0M
|
3
|
|
ASX - By Stock
|
WBT |
Re:
Charts
|
|
EML333
|
4.9K |
2.0M |
2 |
02/11/20 |
02/11/20 |
ASX - By Stock
|
4.9K
|
2.0M
|
2
|
|
ASX - By Stock
|
WBT |
Re:
Charts
|
|
EML333
|
4.9K |
2.0M |
3 |
02/11/20 |
02/11/20 |
ASX - By Stock
|
4.9K
|
2.0M
|
3
|
|
ASX - By Stock
|
WBT |
Re:
fair value
|
|
EML333
|
308 |
94K |
6 |
31/10/20 |
31/10/20 |
ASX - By Stock
|
308
|
94K
|
6
|
|
ASX - By Stock
|
WBT |
Re:
fair value
|
|
EML333
|
308 |
94K |
11 |
31/10/20 |
31/10/20 |
ASX - By Stock
|
308
|
94K
|
11
|
|
ASX - By Stock
|
WBT |
Re:
fair value
|
|
EML333
|
308 |
94K |
3 |
31/10/20 |
31/10/20 |
ASX - By Stock
|
308
|
94K
|
3
|
|
ASX - By Stock
|
WBT |
Re:
fair value
|
|
EML333
|
308 |
94K |
9 |
30/10/20 |
30/10/20 |
ASX - By Stock
|
308
|
94K
|
9
|
|
ASX - By Stock
|
SOR |
Re:
will this get to .21 anytime this year
|
|
EML333
|
39 |
9.6K |
0 |
30/10/20 |
30/10/20 |
ASX - By Stock
|
39
|
9.6K
|
0
|
|
ASX - By Stock
|
WBT |
Re:
fair value
|
|
EML333
|
308 |
94K |
5 |
30/10/20 |
30/10/20 |
ASX - By Stock
|
308
|
94K
|
5
|
|
ASX - By Stock
|
WBT |
Re:
fair value
|
|
EML333
|
308 |
94K |
7 |
30/10/20 |
30/10/20 |
ASX - By Stock
|
308
|
94K
|
7
|
|
ASX - By Stock
|
WBT |
Re:
Weebit - 2021and beyond
|
|
EML333
|
10K |
3.6M |
23 |
28/10/20 |
28/10/20 |
ASX - By Stock
|
10K
|
3.6M
|
23
|
|
ASX - By Stock
|
WBT |
Re:
Charts
|
|
EML333
|
4.9K |
2.0M |
1 |
28/10/20 |
28/10/20 |
ASX - By Stock
|
4.9K
|
2.0M
|
1
|
|
ASX - By Stock
|
WBT |
Re:
Charts
|
|
EML333
|
4.9K |
2.0M |
1 |
28/10/20 |
28/10/20 |
ASX - By Stock
|
4.9K
|
2.0M
|
1
|
|
ASX - By Stock
|
WBT |
Re:
fair value
|
|
EML333
|
308 |
94K |
1 |
27/10/20 |
27/10/20 |
ASX - By Stock
|
308
|
94K
|
1
|
|
ASX - By Stock
|
WBT |
Re:
fair value
|
|
EML333
|
308 |
94K |
6 |
26/10/20 |
26/10/20 |
ASX - By Stock
|
308
|
94K
|
6
|
|
ASX - By Stock
|
WBT |
Re:
Ann: Weebit Nano Q1 FY21 Activities Update & Appendix 4C
|
|
EML333
|
268 |
84K |
13 |
23/10/20 |
23/10/20 |
ASX - By Stock
|
268
|
84K
|
13
|
|
ASX - By Stock
|
WFE |
Re:
WFE (soon to be renamed Pathfinder Resources Limited) Prospectus
|
|
EML333
|
248 |
99K |
1 |
12/10/20 |
12/10/20 |
ASX - By Stock
|
248
|
99K
|
1
|
|
ASX - By Stock
|
WFE |
Re:
WFE (soon to be renamed Pathfinder Resources Limited) Prospectus
|
|
EML333
|
248 |
99K |
0 |
12/10/20 |
12/10/20 |
ASX - By Stock
|
248
|
99K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Anyone else buy in after todays dip/crash?
|
|
EML333
|
211 |
87K |
10 |
11/08/20 |
11/08/20 |
ASX - By Stock
|
211
|
87K
|
10
|
|
ASX - By Stock
|
MSB |
Re:
MSB Trading - Aug 2020 on
|
|
EML333
|
2.3K |
905K |
8 |
11/08/20 |
11/08/20 |
ASX - By Stock
|
2.3K
|
905K
|
8
|
|
ASX - By Stock
|
AN1 |
Re:
Ann: Cellmid Reports on Results of The Doherty Institute Testing
|
|
EML333
|
113 |
29K |
1 |
15/06/20 |
15/06/20 |
ASX - By Stock
|
113
|
29K
|
1
|
|
ASX - By Stock
|
AN1 |
Re:
Ann: Cellmid Reports on Results of The Doherty Institute Testing
|
|
EML333
|
113 |
29K |
0 |
15/06/20 |
15/06/20 |
ASX - By Stock
|
113
|
29K
|
0
|
|
ASX - By Stock
|
AN1 |
Re:
Ann: Cellmid Reports on Results of The Doherty Institute Testing
|
|
EML333
|
113 |
29K |
12 |
15/06/20 |
15/06/20 |
ASX - By Stock
|
113
|
29K
|
12
|
|
ASX - By Stock
|
AN1 |
Re:
Ann: Cellmid Reports on Results of The Doherty Institute Testing
|
|
EML333
|
113 |
29K |
0 |
15/06/20 |
15/06/20 |
ASX - By Stock
|
113
|
29K
|
0
|
|
ASX - By Stock
|
AN1 |
Re:
Ann: Company Update
|
|
EML333
|
149 |
38K |
1 |
10/06/20 |
10/06/20 |
ASX - By Stock
|
149
|
38K
|
1
|
|
ASX - By Stock
|
AN1 |
Re:
Ann: CDY signs Introducer Agreement to broaden product offering
|
|
EML333
|
34 |
12K |
3 |
05/06/20 |
05/06/20 |
ASX - By Stock
|
34
|
12K
|
3
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Remestemcel-L Improves Outcomes in Inflammatory Lung Disease
|
|
EML333
|
143 |
71K |
9 |
02/06/20 |
02/06/20 |
ASX - By Stock
|
143
|
71K
|
9
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Remestemcel-L Improves Outcomes in Inflammatory Lung Disease
|
|
EML333
|
143 |
71K |
11 |
01/06/20 |
01/06/20 |
ASX - By Stock
|
143
|
71K
|
11
|
|
ASX - By Stock
|
AN1 |
Re:
When will CDY start trading again?
|
|
EML333
|
35 |
12K |
4 |
28/05/20 |
28/05/20 |
ASX - By Stock
|
35
|
12K
|
4
|
|
ASX - By Stock
|
AN1 |
Re:
Twitter...again
|
|
EML333
|
12 |
3.8K |
0 |
28/05/20 |
28/05/20 |
ASX - By Stock
|
12
|
3.8K
|
0
|
|
ASX - By Stock
|
AN1 |
Re:
Twitter...again
|
|
EML333
|
12 |
3.8K |
2 |
28/05/20 |
28/05/20 |
ASX - By Stock
|
12
|
3.8K
|
2
|
|
ASX - By Stock
|
AN1 |
Re:
When will CDY start trading again?
|
|
EML333
|
35 |
12K |
2 |
28/05/20 |
28/05/20 |
ASX - By Stock
|
35
|
12K
|
2
|
|
ASX - By Stock
|
AN1 |
Re:
Ann: Cellmid Signs COVID-19 Rapid Diagnostic Supply Agreement
|
|
EML333
|
1.2K |
409K |
0 |
27/05/20 |
27/05/20 |
ASX - By Stock
|
1.2K
|
409K
|
0
|
|
ASX - By Stock
|
AN1 |
Re:
Ann: Cellmid Signs COVID-19 Rapid Diagnostic Supply Agreement
|
|
EML333
|
1.2K |
409K |
0 |
27/05/20 |
27/05/20 |
ASX - By Stock
|
1.2K
|
409K
|
0
|
|
ASX - By Stock
|
AN1 |
Re:
Ann: Cellmid Signs COVID-19 Rapid Diagnostic Supply Agreement
|
|
EML333
|
1.2K |
409K |
0 |
27/05/20 |
27/05/20 |
ASX - By Stock
|
1.2K
|
409K
|
0
|
|
ASX - By Stock
|
AN1 |
Re:
Ann: Cellmid Signs COVID-19 Rapid Diagnostic Supply Agreement
|
|
EML333
|
1.2K |
409K |
1 |
27/05/20 |
27/05/20 |
ASX - By Stock
|
1.2K
|
409K
|
1
|
|
ASX - By Stock
|
AN1 |
Re:
Ann: Cellmid Signs COVID-19 Rapid Diagnostic Supply Agreement
|
|
EML333
|
1.2K |
409K |
0 |
26/05/20 |
26/05/20 |
ASX - By Stock
|
1.2K
|
409K
|
0
|
|
ASX - By Stock
|
AN1 |
Re:
Ann: Cellmid Signs COVID-19 Rapid Diagnostic Supply Agreement
|
|
EML333
|
1.2K |
409K |
3 |
26/05/20 |
26/05/20 |
ASX - By Stock
|
1.2K
|
409K
|
3
|
|
ASX - By Stock
|
AN1 |
Re:
Ann: Cellmid Signs COVID-19 Rapid Diagnostic Supply Agreement
|
|
EML333
|
1.2K |
409K |
2 |
26/05/20 |
26/05/20 |
ASX - By Stock
|
1.2K
|
409K
|
2
|
|
ASX - By Stock
|
AN1 |
Re:
Ann: Cellmid Signs COVID-19 Rapid Diagnostic Supply Agreement
|
|
EML333
|
1.2K |
409K |
7 |
20/05/20 |
20/05/20 |
ASX - By Stock
|
1.2K
|
409K
|
7
|
|
ASX - By Stock
|
MSB |
Re:
Will Moderna Vaccine progress effect MSB SP?
|
|
EML333
|
27 |
13K |
5 |
19/05/20 |
19/05/20 |
ASX - By Stock
|
27
|
13K
|
5
|
|
ASX - By Stock
|
AN1 |
Re:
Ann: Company Update
|
|
EML333
|
149 |
38K |
8 |
18/05/20 |
18/05/20 |
ASX - By Stock
|
149
|
38K
|
8
|
|